ZURICH/BERLIN, April 5 (Reuters) - The Swiss blue-chip SMI was seen opening 0.1 percent easier at 9,559 points on Friday, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks:
The drugmaker has sued Amgen, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.
Swiss investors EOS Holding and Primeo Energie are jointly buying French group EDF’s 25 percent stake in utility Alpiq Holding ALPH.S for 489 million Swiss francs ($489 million), or 70 francs per share. The move by the two minority shareholders aims to consolidate control of Alpiq in Swiss hands and eventually take the power supplier private, they said in a statement.
* Ems Chemie Q1 net sales rose by 1.5 percent to 604 million Swiss francs.
* Orascom Development Holding AG: net losses decreased by 9.2% to CHF 37.3 million in FY 2018 despite one-off historical legacy items of CHF 16.5 million
* Leclanche SA: FY EBITDA loss CHF 39.1 million compared to a loss of CHF 31.8 million previous year
* Admicasa Holding AG: changes in the board of directors and the executive board; suspends Serge Aerne as CEO and director of subsidiaries for duration of ongoing investigations and court cases
FORBO HOLDING AG: CREDIT SUISSE RAISES TARGET PRICE TO SFR 1880 FROM SFR 1850
TEMENOS GROUP AG: CREDIT SUISSE RAISES TARGET PRICE TO SFR 143 FROM SFR 135
STRAUMANN HOLDING AG: HSBC RAISES TARGET PRICE TO SFR 925 FROM SFR 910
PANALPINA WELTTRANSPORT HOLDING AG: HSBC RAISES TARGET PRICE TO SFR 196 FROM SFR 180
No major Swiss economic data due (Reporting by Zurich newsroom and Berlin Speed Desk)